MARKETS / NASDAQ / TECH

NASDAQ · BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) · LARGE CAP

Bio-techne Corp. TECH

18 fiscal years on record · USD · FY2025 reported · SEC filings only

Revenue

$1.2B

▼ 0.4% YoY

Net income

$181.9M

▲ 147.8% YoY

Free cash flow

$263.2M

▲ 2.6% YoY

In brief

What this company does

Bio-Techne and its subsidiaries develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. Through its subsidiaries, Bio-Techne employed approximately 3,100 full-time and part-time employees as of June 30, 2025, of whom approximately 2,300 were in the United States and approximately 800 outside the United States. It is a Minnesota corporation with its global headquarters in Minneapolis, Minnesota. The company manages the business in two operating segments, the Protein Sciences segment and the Diagnostics and Spatial Biology segment. The Protein Sciences segment, representing approximately 72% of net sales in fiscal 2025, comprises the Reagent Solutions division and the Analytical Solutions division. The Diagnostics and Spatial Biology segment, representing approximately 28% of net revenues in fiscal 2025, includes three divisions focused on spatial biology, liquid biopsy, molecular diagnostics kits and products, and diagnostics reagents. The company was founded in 1976 as Research and Diagnostic Systems, Inc. and became publicly traded in 1985 through a merger with Techne Corporation.

Written from the business description in Bio-Techne Corp's annual report to the U.S. Securities and Exchange Commission, filed 22 August 2025. Every sentence was checked against that document before publication.

Growth

USD 1.2B

Revenue, FY2025 · full 18-year series below

Revenue $B Net income $B

FY2025 · Revenue 1.2 · Net income 0.2

Compound annual growth

Revenue

+2.2%

+5.5%

+9.3%

+10.0%

EPS, diluted

−13.0%

Dividend / share

+0.0%

Returned to shareholders

−0.2%

+0.1%

+0.5%

+1.5%

3 yrs

5 yrs

10 yrs

15 yrs

Revenue compounded at +5.5% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

15 cents

of every revenue dollar became profit

Operating margin Net margin

FY2025 · Operating 20.7% · Net 15.0%

ROE

FY2025 · ROE 9.0%

Gross margin65.8%

Operating margin20.7%

Net margin15.0%

Return on assets7.1%

EBITDAUSD 349.2M

Each USD of equity produced 9 cents of profit this year.

Cash & shareholders

USD 49.9M

returned in FY2025 · dividends + net buybacks

Free cash flow $M

FY2025 · FCF 263.2

Net buybacks $M Dividends $M

FY2025 · Dividends 49.9 · Net buybacks -38.9

Dividends paidUSD 49.9M

Net buybacksUSD -38.9M

Share of profit27.4%

Consecutive raises—

USD 49.9M in dividends — 27% of the year's profit went back to shareholders.

Total assetsUSD 2.6B

EquityUSD 2.1B

CashUSD 264.7M

Gross debtUSD 200.0M

Net debtUSD -64.7M

Current ratio4.55×

The company holds more cash than debt.

The 18-year record

18 fiscal years

Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative

Metric	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011	2010	2009	2008
Revenue $B	1.2	1.2	1.2	1.1	1.1	0.9	0.7	0.7	0.6	0.6	0.5	0.5	0.4	0.3	0.3	0.3	0.3	0.3
Operating income $B	0.3	0.1	0.2	0.3	0.3	0.2	0.2	0.1	0.1	0.1	0.2	0.1	0.2	0.0	0.2	0.2	0.2	0.2
EBITDA $B	0.3	0.2	0.3	0.4	0.4	0.3	0.2	0.2	0.2	0.2	0.2	0.2	0.2	0.0	0.2	0.2	0.2	0.2
Income tax $B	0.1	0.0	0.0	0.1	0.0	0.0	0.0	0.0	−0.0	0.0	0.0	0.0	0.1	0.0	0.0	0.1	0.0	0.1
Net income $B	0.2	0.1	0.2	0.3	0.3	0.1	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
Free cash flow $B	0.3	0.3	0.2	0.2	0.3	0.3	0.2	0.2	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1	0.1
EPS, diluted $	1.16	0.46	1.05	1.76	1.66	0.87	5.82	2.47	3.31	2.03	2.80	2.89	3.00	3.05	3.04	3.02	2.94	2.78
Dividend / sh $	0.32	0.32	0.32	0.32	0.32	0.32	1.28	1.28	1.28	1.28	1.28	1.27	1.23	1.18	1.11	1.07	1.03	0.75
Payout %	27	69	30	18	18	35	21	50	38	62	46	44	41	39	37	35	35	27
ROE %	9.0	3.7	8.3	15.6	16.7	9.5	18.0	8.6	12.4	8.3	12.1	13.1	14.5	15.9	17.8	20.6	22.9	23.1
Shares out B	0.16	0.15	0.16	0.16	0.16	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	0.04	·

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance

Company facts, as filed

How we verify · 0 failures in 88 reconciliationsAUDITED

Reconciled in 18 of 19 fiscal years. 7 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures

ActivityBiological Products, (No Diagnostic Substances)

Listed onNASDAQ

Incorporated inMinnesota

Fiscal year endsJune 30

Data on record since2008